AstraZeneca Stock - FDA approves Truqap combo for prostate cancer
17.06.2026 - 17:16:54 | ad-hoc-news.de
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 17:15 CET. Details in the imprint.
AstraZeneca (GB0009895292) expanded its oncology portfolio this week as the US Food and Drug Administration approved a Truqap combination therapy for certain prostate cancer patients, according to a Nasdaq news summary on the FDA decision. The regulatory green light adds another potential growth driver for the drugmaker.
All news and analysis on AstraZeneca stock
Key figures, regulatory updates and strategy insights on AstraZeneca are bundled in the ad-hoc-news topic overview and on the company’s investor-relations pages.
What the FDA approval covers
According to the latest Nasdaq market activity note, the US regulator cleared a combination based on AstraZeneca’s targeted therapy Truqap for an additional prostate cancer indication, adding to its existing approvals in other tumor types. The update underscores the group’s focus on precision oncology.
The Truqap decision follows a series of oncology milestones for AstraZeneca this year, including priority review status for Ultomiris in IgA nephropathy reported by tradersunion.com in mid-June. Management continues to emphasize late-stage oncology assets as core growth drivers.
Operations and strategy on Wednesday
On this Wednesday, the strategic picture centers on AstraZeneca’s push to deepen its cancer portfolio while maintaining scale in cardiovascular, renal and metabolic diseases. The group has repeatedly highlighted its ambition to deliver industry-leading revenue growth through 2030.
First-quarter 2026 results, published earlier in the year, showed solid top-line momentum but were followed by a roughly 7% decline in the US-listed stock over three months, according to Zacks Investment Research. The combination of fresh approvals and recent share weakness keeps the strategic execution in sharp focus.
How the company makes money
AstraZeneca generates most of its revenue from prescription medicines in oncology, cardiovascular, renal and metabolic diseases, and respiratory conditions. Flagship oncology products include Tagrisso for lung cancer, Imfinzi for several solid tumors, and newer targeted therapies such as Truqap.
Where the stock trades today
The shares of AstraZeneca (GB0009895292) trade in London under the ticker AZN at about GBP 133.20 as of 06/17/2026, 16:30 BST, according to recent price data from MarketBeat.
Key facts on AstraZeneca stock
- Company: AstraZeneca plc
- ISIN: GB0009895292
- WKN: 886455
- Ticker: AZN
- Venue: London Stock Exchange
- Price (as of 06/17/2026, 16:30 BST): 133.20 GBP
- Market cap: approximately 206,000,000,000 GBP (as of 06/17/2026)
- Sector / Industry: Health Care / Pharmaceuticals & Biotechnology
- Index membership: FTSE 100, Stoxx Europe 600
- Next earnings date: 07/25/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
